3Sadeghi B,Arvieux C,Glehen O,et al.Peritoneal carcinomatosis from nongynecologic malignancies:rusults of the EVOCAPE 1 multicentric prospective study[J].Cancer,2000,88(2):358-363.
4Mackey JR,Venner PM.Malignant ascites:demographics,thera-peutic efficacy and predictors of survival[J].Can J Oncol,1996,6(2):474-480.
5Silva SD,Agostini M,Nishimoto IN,et al.Expression of fatty acid synthase,ErbB2 and Ki-67 in head and neck squamous cell carci-noma.A clinicopathological study[J].Oral Oncol.2004,40(7):688-696.
6Garrison RN,Kaelin LD,Galloway RH,et al.Malignant ascites.Clinical and experimental observation[J].Ann Surg,1986,203(6):644-651.
7Rodriguez-Panadero F,Borderas Naranjo F,Lopez-Mejias J.Pleu-ral metastatic tumours and effiusions.Frequency and pathogenic mechanisms in a post-mortem series[J].Eur Respir J,1989,2(4):366-369.
8Macke~ Jg,Venner ffM.Malignant ascites:demogr~phics therapeutic efficacy and predictors of surviv&l[J].Can J 0nco1,1996,6(2)~474-480.
9Scholzen T,Gerdes J.The Ki-67 protein:from the known &nd the unknown[J]. Oell Physiol, 2000, 182(3), 31 ] -322.
10Bluvshtein GA,Lysenko VG,Zakharova NB et aI.Tumor ma~kers p53, sFAS,FASL,CEA &nd CA 199 in evaluating the effectiveness of surgical and pharmaco-nutritional treatment of patients with gastric cancer[J]. Eksp Klin Gastroentero/, 2012,2 : 41-49.
